A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs PF-06863135 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 May 2018 Planned End Date changed from 13 Apr 2022 to 4 May 2022.
- 10 May 2018 Planned primary completion date changed from 3 Aug 2021 to 24 Aug 2021.
- 08 May 2018 Planned End Date changed from 29 Nov 2021 to 13 Apr 2022.